KRAS and glioblastoma: In elderly GBM patients under the WHO5 classification, KMT5B (p = 0.082), KRAS (p = 0.1), and PPM1D (p = 0.055) alteration were associated with poorer OS (Figure 3B), and in younger GBM patients under the WHO5 classification, CDK6 (p = 0.092), CIC (p = 0.025), KMT5B (p = 0.042), PIK3R1 (p = 0.012), and TP53 (p = 0.0048) were predictors of prognosis (Figure 3C).